Form 4: Xeris Director Sells $309K in Stock

Xeris Biopharma Director Dawn Halkuff sold 42,500 shares of common stock for approximately $309,000 on August 12, 2025, under a pre-planned Rule 10b5-1 program.

Summary

• Director Dawn Halkuff sold 42,500 shares of Xeris Biopharma Holdings, Inc. common stock.
• The transaction occurred on August 12, 2025.
• The shares were sold at a weighted average price of $7.2759 per share, totaling approximately $309,270.75.
• The sale price ranged from $7.190 to $7.450 per share.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.
• Following the sale, Dawn Halkuff directly owns 115,000 shares and indirectly owns 5,410 shares through the Dawn Halkuff Revocable Trust.

Sentiment

Score: 5

Explanation: The sale of shares by a director is generally viewed as neutral to slightly negative, but the disclosure that it was executed under a Rule 10b5-1 plan mitigates concerns that it was based on new, non-public information.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on new material non-public information.

Negatives

• A director sold a significant number of shares (42,500 shares) of common stock.

Risks

• The sale of shares by a director, even if pre-planned, could be perceived negatively by some investors, potentially impacting market sentiment.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitors.

Related Party Transactions

• Indirect beneficial ownership of 5,410 shares is held through the Dawn Halkuff Revocable Trust U/A DTD 08/25/2017.

Stakeholder Impact

• Shareholders: Potential slight negative sentiment due to insider selling, though largely mitigated by the disclosure of a Rule 10b5-1 plan.

Key Dates

Recommendation

The filing reports a routine insider sale executed under a pre-planned Rule 10b5-1 program. While insider sales can sometimes be a negative signal, the pre-scheduled nature of this transaction suggests it is not based on new, adverse material information. Therefore, it does not significantly alter the investment thesis for Xeris Biopharma Holdings, Inc., warranting a 'hold' recommendation based solely on this filing.

Keywords

Xeris Biopharma, XERS, insider trading, Form 4, stock sale, director, beneficial ownership, Rule 10b5-1